Quantification of SARS-CoV-2 neutralizing antibody by wild-type plaque reduction neutralization, microneutralization and pseudotyped virus neutralization assays
…, PJ Brown, EJ Penn, K Thomas, G Kulnis, B Hallis… - Nature protocols, 2021 - nature.com
… b, Counts should be arranged in a new worksheet, as shown, and saved as a .csv file. c,
Following analysis using the R script supplied, a graph is generated and automatically saved as …
Following analysis using the R script supplied, a graph is generated and automatically saved as …
Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial
Background The pandemic of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
might be curtailed by vaccination. We assessed the safety, reactogenicity, and …
might be curtailed by vaccination. We assessed the safety, reactogenicity, and …
[HTML][HTML] Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV …
…, S Todd, C Twelves, RC Read, S Charlton, B Hallis… - The Lancet, 2021 - thelancet.com
… 18 sites were split into three groups (A, B, and C). Within each site group (A, B, or C),
participants were randomly assigned to an experimental vaccine or control. Group A received NVX-…
participants were randomly assigned to an experimental vaccine or control. Group A received NVX-…
[HTML][HTML] Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind …
…, M Fuskova, D Gbesemete, C Green, B Hallis… - The Lancet, 2020 - thelancet.com
Background Older adults (aged ≥70 years) are at increased risk of severe disease and
death if they develop COVID-19 and are therefore a priority for immunisation should an …
death if they develop COVID-19 and are therefore a priority for immunisation should an …
[PDF][PDF] Reduced neutralization of SARS-CoV-2 B. 1.1. 7 variant by convalescent and vaccine sera
…, J Slon-Campos, C López-Camacho, B Hallis… - Cell, 2021 - cell.com
… We examine the ability of B.1.1.7 to evade antibody responses elicited by natural SARS-CoV-2 …
B.1.1.7 is harder to neutralize than parental virus, compromising neutralization by some …
B.1.1.7 is harder to neutralize than parental virus, compromising neutralization by some …
Safety and immunogenicity of heterologous versus homologous prime-boost schedules with an adenoviral vectored and mRNA COVID-19 vaccine (Com-COV): a …
Background Use of heterologous prime-boost COVID-19 vaccine schedules could facilitate
mass COVID-19 immunisation. However, we have previously reported that heterologous …
mass COVID-19 immunisation. However, we have previously reported that heterologous …
Robust SARS-CoV-2-specific T cell immunity is maintained at 6 months following primary infection
…, T Brooks, S Taylor, J Hewson, B Hallis… - Nature …, 2021 - nature.com
The immune response to SARS-CoV-2 is critical in controlling disease, but there is concern
that waning immunity may predispose to reinfection. We analyzed the magnitude and …
that waning immunity may predispose to reinfection. We analyzed the magnitude and …
Immunogenicity, safety, and reactogenicity of heterologous COVID-19 primary vaccination incorporating mRNA, viral-vector, and protein-adjuvant vaccines in the UK …
Background Given the importance of flexible use of different COVID-19 vaccines within the
same schedule to facilitate rapid deployment, we studied mixed priming schedules …
same schedule to facilitate rapid deployment, we studied mixed priming schedules …
Phase 1/2 trial of SARS-CoV-2 vaccine ChAdOx1 nCoV-19 with a booster dose induces multifunctional antibody responses
…, A Flaxman, M Fuskova, A Gorringe, B Hallis… - Nature medicine, 2021 - nature.com
… Helper T cells are also critical to support B cell function for the initial and continued production
of antibody. However, the types of T cell responses elicited by this, and other SARS-CoV-…
of antibody. However, the types of T cell responses elicited by this, and other SARS-CoV-…
Performance characteristics of five immunoassays for SARS-CoV-2: a head-to-head benchmark comparison
…, N Gent, D Georgiou, CJ Groves, B Hallis… - The Lancet Infectious …, 2020 - thelancet.com
Background Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has caused a
global pandemic in 2020. Testing is crucial for mitigating public health and economic effects. …
global pandemic in 2020. Testing is crucial for mitigating public health and economic effects. …
